Researchers have discovered a promising new approach to lung cancer treatment. A small molecule called AVJ16 selectively blocks the cancer-driving protein IGF2BP1, halting tumor growth in preclinical studies and killing cancer cells in patient-derived models—while leaving healthy cells unharmed.